Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

Good morning and welcome to Novavax First Quarter 2025 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

On a per-share basis, the Gaithersburg, Maryland-based company said it had net income of $2.93. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...